Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO)
Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are started with an antiresorptive treatment, i.e. drugs t...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2017-08-01
|
| سلاسل: | Swiss Medical Weekly |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.smw.ch/index.php/smw/article/view/2352 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|